Want to see RNTX full AI Analyst Report?
Top Page
Rein Therapeutics
(NASDAQ:RNTX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.78
▲(2.11% Upside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance (no revenue, large losses, and ongoing cash burn) and bearish technicals (below key moving averages with negative MACD). Corporate-event risk is elevated due to the Nasdaq delisting notice, while the debt-free balance sheet provides only limited offset.
Positive Factors
FDA Fast Track Designation
Fast Track status may accelerate FDA interaction and development of LTI-03, improving the program’s regulatory path and potential strategic value if clinical efficacy and safety are demonstrated.
Negative Factors
Pre-Revenue Business Model
Rein has no commercial revenue to offset research and development costs, leaving results dependent on clinical success, regulatory approval and future financing or licensing transactions.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA Fast Track Designation
Fast Track status may accelerate FDA interaction and development of LTI-03, improving the program’s regulatory path and potential strategic value if clinical efficacy and safety are demonstrated.
Read all positive factors
Rein Therapeutics (RNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$65.74M
Dividend YieldN/A
Average Volume (3M)228.95K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS Growth36.23%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.83
Shares Outstanding86,267,030
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside689.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Rein Therapeutics Business Overview & Revenue Model
Company Description
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is ...
How the Company Makes Money
As a clinical-stage biotechnology company, Rein Therapeutics does not primarily generate revenue from selling approved products. Its ability to make money in the future is expected to depend on successfully developing and obtaining regulatory appr...
Rein Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -21.04M | -50.58M | -28.05M | -15.23K | -27.16K | -26.04K |
| Net Income | -49.76M | -49.87M | -62.88M | -15.73K | -27.33K | -26.16K |
Balance Sheet | ||||||
| Total Assets | 65.97M | 24.16M | 69.24M | 106.01M | 22.01M | 48.48M |
| Cash, Cash Equivalents and Short-Term Investments | 40.65M | 3.21M | 12.87M | 17.31M | 21.24M | 45.93M |
| Total Debt | 0.00 | 0.00 | 0.00 | 48.00K | 33.00K | 162.00K |
| Total Liabilities | 55.77M | 7.24M | 14.85M | 99.12M | 3.38M | 4.58M |
| Stockholders Equity | 10.20M | 16.92M | 54.39M | 6.89M | 18.62M | 43.90M |
Cash Flow | ||||||
| Free Cash Flow | -18.83M | -19.36M | -22.29M | -19.81M | -24.86M | -23.91M |
| Operating Cash Flow | -18.83M | -19.36M | -22.29M | -19.81M | -24.86M | -23.75M |
| Investing Cash Flow | -35.07M | 0.00 | 0.00 | 16.20M | 26.46M | -35.92M |
| Financing Cash Flow | 56.77M | 9.76M | 17.82M | 15.79M | 0.00 | 55.66M |
Rein Therapeutics Technical Analysis
Negative
0.76
Price Trends
0.86
Negative
1.04
Negative
1.17
Negative
Market Momentum
-0.02
Negative
40.46
Neutral
4.99
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNTX, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.86, and below the 200-day MA of 1.17, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 40.46 is Neutral, neither overbought nor oversold. The STOCH value of 4.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNTX.
Rein Therapeutics Risk Analysis
Rein Therapeutics disclosed 68 risk factors in its most recent earnings report. Rein Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rein Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $59.22M | -6.01 | -50.77% | ― | 327.25% | 85.65% | |
45 Neutral | $73.13M | -1.66 | -103.08% | ― | -6.96% | 32.77% | |
45 Neutral | $74.64M | -1.27 | -1266.43% | ― | ― | 49.43% | |
44 Neutral | $65.74M | -0.41 | -234.45% | ― | ― | 36.23% | |
42 Neutral | $109.23M | -3.38 | 1020.21% | ― | ― | 2.05% |
* Healthcare Sector Average
RNTX
Rein Therapeutics
0.75
-0.60
-44.52%
ONCY
Oncolytics Biotech
0.84
-0.31
-27.13%
CRDF
Cardiff Oncology
0.99
-0.96
-49.08%
XBIT
XBiotech
2.30
-0.72
-23.84%
ELTX
Elicio Therapeutics
2.70
-7.65
-73.91%
XLO
Xilio Therapeutics
8.95
-0.85
-8.68%
Rein Therapeutics Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price
Negative
Aug 27, 2026
On August 21, 2026, Rein Therapeutics received a delisting notice from the Nasdaq Stock Market after its common stock’s closing bid price remained below $1.00 per share for 30 consecutive trading days, breaching Nasdaq Listing Rule 5550(a)(1...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Rein Therapeutics Shareholders Approve Governance and Stock Changes
Positive
Jul 21, 2026
On July 20, 2026, Rein Therapeutics held its 2026 Annual Meeting of Stockholders, at which shareholders elected two Class III directors, Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D., to serve on the board until the 2029 annual meeting. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.